{
  "id": 18661568,
  "title": "Bristol Myers Squibb director Julia Haller sells $240,578 in stock",
  "url": "https://urgent.news/2026/11/07/bristol-myers-squibb-director-julia-haller-sells-240-578-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-07T07:01:11.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/bristol-myers-squibb-director-julia-haller-sells-240578-in-stock-93CH-5009733"
  },
  "original_language": "en",
  "account": null,
  "summary": "Bristol Myers Squibb Co. (NYSE:BMY) director Julia Haller sold 3,800 shares of common stock on November 5, 2026, for a total of $240,578. The shares were sold at $63.31 each, following a current stock price of $62.14. Despite this sale, Haller still holds 30,279 shares of the company. BMY, a pharmaceutical giant with a market capitalization of $129 billion, has maintained dividend payments for 56 consecutive years, offering a 4.06% yield. Analysts have noted that BMY stock appears undervalued based on its Fair Value assessment, with a P/E ratio of 13.82. Bristol-Myers Squibb reported strong third-quarter results, leading to an increase in full-year revenue guidance and positive reactions from analysts, who have raised price targets and maintained Buy ratings. However, concerns remain regarding the upcoming loss of exclusivity for Eliquis in European Union markets, which have prompted some analysts to lower their price targets.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}